Trial Information
Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases
Inclusion Criteria:
- ≥ to 18 years of age
- Diagnosed with a metastatic malignancy
- histologically proven in oligometastatic disease or by clinical suspicion in widely
metastatic disease
- by conventional radiographs, cross sectional imaging and/or scintigraphy
- Scheduled for an orthopaedic operative intervention for skeletal metastases at MSKCC
including, not limited to the following:
- Resection
- Intramedullary Fixation
- Prophylactic fixation
- Curettage and cementation
- Internal fixation
- Arthroplasty
- Spine stabilization
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
serum inflammatory cytokines
Outcome Description:
Whether the addition of serum inflammatory cytokines improves the robustness of an existing, validated Bayesian Belief network trained to estimate survival in human patients with operative skeletal metastases.
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
John Healey, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
11-121
NCT ID:
NCT01470105
Start Date:
November 2011
Completion Date:
November 2014
Related Keywords:
- Bone Metastases
- questionnaire
- 11-121
- Neoplasm Metastasis
- Neoplasms, Second Primary
- Bone Neoplasms
- Bone Marrow Diseases
Name | Location |
Memorial Sloan-Kettering Cancer Center 1275 York Avenue |
New York, New York 10021 |
Naval Medical Research Center |
Bethesda, Maryland 20889 |